Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and ...

Eli Lilly and Company’s LLY stock has risen ... Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past year. These included Omvoh for ulcerative ...

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective ...

Eli Lilly reduces price of weight loss medicine Zepbound, offering discounts to patients. Obesity rates skyrocket in America.

Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...